The ultra-small 1cm² patch, which only needs to be applied once a week, dramatically increases user convenience

超小型1cm²贴片，每周只需要使用一次，大大提高了用户的便利性

Daewoong Therapeutics employs the 'CLOPAM' platform to develop 'advanced formulations,' with plans for commercialization by 2028

Daewoong Therapeutics采用“CLOPAM”平台开发“先进配方”，并计划到2028年商业化

CEO Seung-Ho Jeon states, 'By developing the GLP-1 analogue patch-type formulation, we aim to meet the unmet needs of patients and medical professionals.'

首席执行官Seung-Ho Jeon表示，“通过开发GLP-1类似贴剂型配方，我们的目标是满足患者和医疗专业人员未满足的需求。”

SEOUL, South Korea, Nov. 6, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEOs Seng-Ho Jeon and Chang-Jae Lee) announced on the 6th that it will commence full-scale development of an obesity treatment utilizing a microneedle patch loaded with GLP-1 (Glucagon-like peptide-1) analogues. The microneedle technology, which involves applying an ultra-small 1cm² patch to the arm or abdomen, represents an advanced formulation that significantly enhances user convenience over traditional obesity treatments.

韩国首尔，2023年11月6日/PRNewswire/-大丰制药（首席执行官Seng-Ho Jeon和Chang-Jae Lee）于6日宣布，将开始利用微针贴片全面开发肥胖治疗用GLP-1（胰高血糖素样肽-1）类似物负载。微针技术涉及在手臂或腹部应用超小型1cm²贴片，代表了一种先进的配方，与传统的肥胖治疗相比，显着提高了用户的便利性。

Daewoong Pharmaceutical is set to initiate Phase 1 clinical trials early next year, with the goal of commercializing the product by 2028..

Daewoong Pharmaceutical将于明年年初启动第一阶段临床试验，目标是到2028年将产品商业化。。

Continue Reading

继续阅读

Daewoong Pharmaceutical Microneedle Platform

Daewoong Pharmaceutical Microneedle Platform

The company is developing an innovative, painless microneedle obesity treatment that can be applied weekly to the arms or abdomen, delivering medication directly through the microvasculature, offering a convenient alternative to traditional, injectable GLP-1 analogue therapies. It maintains the efficacy of existing injectables and offers the significant benefit of room temperature storage, eliminating the need for a cold storage system.

该公司正在开发一种创新的无痛微针肥胖治疗方法，每周可应用于手臂或腹部，直接通过微血管输送药物，为传统的可注射GLP-1类似物治疗提供便利的替代方案。它保持现有注射剂的功效，并提供室温储存的显着益处，无需冷藏系统。

This is a marked improvement over oral obesity treatments, which suffer from low absorption rates of about 1% bioavailability and often cause unpleasant side effects such as vomiting, nausea, and diarrhea..

这是口服肥胖治疗的显着改善，其具有约1%生物利用度的低吸收率并且经常引起令人不快的副作用，例如呕吐，恶心和腹泻。。

Daewoong Therapeutics (CEO Bokki Kang), a subsidiary of Daewoong Pharmaceutical, has completed preclinical studies and compiled data for a microneedle patch within the Semaglutide series, a GLP-1 analogue, using its proprietary 'CLOPAM' (Closed-Packed Aeroperssured Microneedle) platform. This platform is secured by 6 international (Patent Cooperation Treaty, PCT) and 23 domestic patents, of which 5 are registered, encompassing various aspects of manufacturing and packaging.

Daewoong Pharmaceutical的子公司Daewoong Therapeutics（首席执行官Bokki Kang）已经完成了临床前研究，并使用其专有的'CLOPAM'（封闭式气雾剂微针）完成了Semaglutide系列GLP-1类似物内微针贴片的数据）平台。该平台受6项国际（专利合作条约，PCT）和23项国内专利保护，其中5项已注册，涵盖制造和包装的各个方面。

The technology addresses previous challenges, significantly enhancing drug uniformity, preventing contamination, and ensuring stability. The microneedle manufacturing technology preserves the integrity of the biodegradable needles, which are sensitive to moisture and impact, until they are used. These soluble microneedles release the drug into the body as they dissolve..

该技术解决了以前的挑战，显着提高了药物的均匀性，防止污染并确保了稳定性。微针制造技术保留了可生物降解针的完整性，这些针在使用前对水分和冲击敏感。这些可溶性微针在溶解时将药物释放到体内。。

Morgan Stanley forecasts a substantial expansion in the global obesity treatment market, with expectations to reach 104 trillion won by 2030. Daewoong Pharmaceutical is poised to enter this market with its innovative microneedle obesity treatment by 2028, aiming to revolutionize the sector by addressing the limitations of current therapies, especially in improving treatment adherence—a significant challenge highlighted by Eli Lilly's CSO, Dr.

摩根斯坦利预测全球肥胖治疗市场将大幅扩张，预计到2030年将达到104万亿。Daewoong Pharmaceutical有望在2028年之前通过其创新的微针肥胖治疗进入该市场，旨在通过解决当前疗法的局限性来彻底改变该行业，特别是在提高治疗依从性方面-礼来公司CSO博士强调的一项重大挑战。

Dan Skovronsky. This novel treatment, nearing Phase 1 clinical trials, could help prevent weight regain post-GLP-1 analogue use by mimicking the incretin hormone to suppress appetite and regulate blood sugar, thus aiding in the management of obesity and diabetes.Seng-Ho Jeon, CEO of Daewoong Pharmaceutical, remarked, 'Last year, Daewoong Pharmaceutical declared the '2030 Global Formulation No.1' vision and has since been dedicated to new administration route technology, specifically microneedles.

Dan Skovronsky。这种接近1期临床试验的新型治疗方法可以通过模拟肠降血糖素激素来抑制食欲和调节血糖，从而帮助控制肥胖和糖尿病，从而帮助预防体重恢复后GLP-1类似物的使用。Daewoong Pharmaceutical首席执行官Seng-Ho Jeon表示，“去年，Daewoong Pharmaceutical宣布了'2030全球配方No.1'的愿景，并一直致力于新的管理路线技术，特别是微针。

We aim to fulfill the unmet needs of medical professionals and patients by developing a patch-type formulation of GLP-1 analogues, which are garnering global attention.'About Daewoong TherapeuticsDaewoong Therapeutics, a member of the Daewoong Group since February 2019, specializes in R&D for medical and pharmaceutical breakthroughs.

我们的目标是通过开发引起全球关注的GLP-1类似物贴剂型制剂来满足医疗专业人员和患者未满足的需求关于Daewoong Therapeutics Daewoong Therapeutics，自2019年2月起担任Daewoong Group的成员，专门从事医药突破的研发工作。

Its primary focus areas include microneedle drug delivery systems, treatments for eye diseases, and small molecule drugs for cancer. The company recently received Phase 1 IND approval for the first eye drop treatment for diabetic retinopathy, utilizing Enavogliflozin from Daewoong Pharmaceutical's Envlo.Forward-Looking StatementsThis press release contains forward-looking statements that are based on the current beliefs and expectations of Daewoong Pharmaceutical's management.

其主要重点领域包括微针给药系统，眼病治疗和癌症小分子药物。该公司最近获得了第一阶段IND批准，用于糖尿病视网膜病变的第一次滴眼液治疗，使用了Daewoong Pharmaceutical's Envlo的Enavogliflozin。前瞻性声明本新闻稿包含基于目前Daewoong Pharmaceutical's的信念和期望的前瞻性声明。管理层。

Factors that could cause or contr.

可能导致或控制的因素。